SLC5A2
Encyclopedia
The sodium/glucose cotransporter 2 (SGLT2) is a protein
that in humans is encoded by the SLC5A2 (solute carrier family 5 (sodium/glucose cotransporter)) gene
.
which are sodium-dependent glucose
transport proteins. SGLT2 is the major cotransporter involved in glucose reabsorption in the kidney.
, Canagliflozin
, ASP-1941, and six other SGLT2 inhibitors are in clinical trials for diabetes.
Protein
Proteins are biochemical compounds consisting of one or more polypeptides typically folded into a globular or fibrous form, facilitating a biological function. A polypeptide is a single linear polymer chain of amino acids bonded together by peptide bonds between the carboxyl and amino groups of...
that in humans is encoded by the SLC5A2 (solute carrier family 5 (sodium/glucose cotransporter)) gene
Gene
A gene is a molecular unit of heredity of a living organism. It is a name given to some stretches of DNA and RNA that code for a type of protein or for an RNA chain that has a function in the organism. Living beings depend on genes, as they specify all proteins and functional RNA chains...
.
Function
SGLT2 is a member of the sodium glucose cotransporter familySodium-glucose transport proteins
Sodium-dependent glucose cotransporters are a family of glucose transporter found in the intestinal mucosa of the small intestine and the proximal tubule of the nephron . They contribute to renal glucose reabsorption...
which are sodium-dependent glucose
Glucose
Glucose is a simple sugar and an important carbohydrate in biology. Cells use it as the primary source of energy and a metabolic intermediate...
transport proteins. SGLT2 is the major cotransporter involved in glucose reabsorption in the kidney.
SGLT2 inhibitors for diabetes
dapagliflozinDapagliflozin
Dapagliflozin is an experimental drug being studied by Bristol-Myers Squibb in partnership with AstraZeneca as a potential treatment for type 1 and 2 diabetes...
, Canagliflozin
Canagliflozin
Canagliflozin is an experimental drug being developed by Johnson & Johnson for the treatment of type 2 diabetes. It is an inhibitor of subtype 2 sodium-glucose transport protein , which is responsible for at least 90% of the glucose reabsorption in the kidney. Blocking this transporter causes...
, ASP-1941, and six other SGLT2 inhibitors are in clinical trials for diabetes.